SEC Company Response from CASSAVA SCIENCES INC (FLNA) (CIK 0001069530) (FLNA) — Nov 25, 2009
CASSAVA SCIENCES INC (FLNA) (CIK 0001069530)
Date: Nov. 25, 2009 · CIK: 0001069530 · Accession: 0001193125-09-242566
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR AND FACSIMILE (202) 772-9198 Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey P. Riedler Nu Ri Jung Re: Pain Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2008 Filed February 13, 2009
Dear Mr. Riedler, Ms. Hayes and Ms. Jung:
On behalf of Pain Therapeutics, Inc. (the “Company”), this letter is being submitted in reference to the Securities and Exchange Commission’s (the “Commission”) letter to Peter S. Roddy, Vice President and Chief Financial Officer of the Company, dated November 9, 2009 (the “Comment Letter”).
The Company is working expeditiously to respond to the Comment Letter. However, in order to fully address the comments from the staff of the Commission (the “Staff”) and to allow the Company an opportunity to comply with the confidentiality provisions of contracts with third parties as to which the Staff has asked the Company to provide further disclosure of terms that are not currently in the public domain, the Company respectfully requests an extension of time to respond to the inquiries contained in the Comment Letter. The Company currently anticipates submitting a response to the Comment Letter on or before December 4, 2009.
Please do not hesitate to contact me (650-565-3854) or Peter Roddy, the Company’s Vice President and Chief Financial Officer (650-645-1930), with any concerns you may have regarding the timetable described above. Thank you for your consideration.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI
Show Raw Text
CORRESP 1 filename1.htm Correspondence November 25, 2009 VIA EDGAR AND FACSIMILE (202) 772-9198 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Suzanne Hayes Nu Ri Jung Re: Pain Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2008 Filed February 13, 2009 Dear Mr. Riedler, Ms. Hayes and Ms. Jung: On behalf of Pain Therapeutics, Inc. (the “Company”), this letter is being submitted in reference to the Securities and Exchange Commission’s (the “Commission”) letter to Peter S. Roddy, Vice President and Chief Financial Officer of the Company, dated November 9, 2009 (the “Comment Letter”). The Company is working expeditiously to respond to the Comment Letter. However, in order to fully address the comments from the staff of the Commission (the “Staff”) and to allow the Company an opportunity to comply with the confidentiality provisions of contracts with third parties as to which the Staff has asked the Company to provide further disclosure of terms that are not currently in the public domain, the Company respectfully requests an extension of time to respond to the inquiries contained in the Comment Letter. The Company currently anticipates submitting a response to the Comment Letter on or before December 4, 2009. Please do not hesitate to contact me (650-565-3854) or Peter Roddy, the Company’s Vice President and Chief Financial Officer (650-645-1930), with any concerns you may have regarding the timetable described above. Thank you for your consideration. Sincerely, WILSON SONSINI GOODRICH & ROSATI Professional Corporation /s/ Gavin McCraley Gavin McCraley cc: Peter S. Roddy Pain Therapeutics, Inc. Michael O’Donnell, Esq. Wilson Sonsini Goodrich & Rosati, Professional Corporation